Treeline Biosciences develops precision medicines utilizing advanced protein engineering and computational biology to target specific cancer pathways and other serious diseases. The company aims to improve patient outcomes by creating tailored therapies that address the limitations of traditional treatment approaches.
Funding
$894.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often lack specificity, leading to off-target effects and limited efficacy against certain cancer subtypes. Developing targeted therapies requires a deep understanding of cancer biology and advanced techniques to engineer proteins that selectively interact with disease-causing pathways.
Solution
Treeline Biosciences develops precision medicines by integrating advanced protein engineering and computational biology to target specific cancer pathways and other serious diseases. The company focuses on creating tailored therapies that address the limitations of traditional treatment approaches by selectively modulating disease pathways. Treeline's approach involves a balanced internal R&D team across biology, chemistry, protein sciences, and computation, allowing them to work on long lead time projects and exploratory programs. The company leverages internal infrastructure and talent to discover drugs, complemented by external CROs for scale and specific capabilities.
Target Audience
The primary target audience includes patients with cancer and other serious diseases who can benefit from more targeted and effective therapies.
Features
- Advanced protein engineering platform for creating highly specific therapeutic proteins
- Computational biology tools for identifying and validating novel cancer targets
- Internal R&D team with expertise in biology, chemistry, protein sciences, and computation
- Focus on long lead time projects and exploratory programs